Clinical Trials on Relapsed Acute Lymphoblastic Leukemia in United States

Total 2853 results

Emory University

Terminated

AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia (BMTAMD3100)

Pediatric Acute Myeloblastic Leukemia, Relapsed | Pediatric Acute Lymphoblastic Leukemia, Relapsed

United States
Tanja Andrea Gruber

Recruiting

Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)

Acute Lymphoblastic Leukemia, Pediatric | Refractory Acute Lymphoblastic Leukemia | Relapsed Acute Lymphoblastic Leukemia

United States
Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin

Recruiting

CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL (CAR-20/19-T)

Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved Remission

United States
ECOG-ACRIN Cancer Research Group

Recruiting

Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | Lymphoblasts 5 Percent or More of Bone Marrow Nucleated Cells

United States
Michael Burke
Amgen

Recruiting

Blinatumomab Bridging Therapy

Refractory B Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia

United States
Julio Barredo, MD
Takeda

Completed

Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL

Refractory Acute Lymphoblastic Leukemia | Relapsed Acute Lymphoblastic Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Jazz Pharmaceuticals

Completed

Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Relapsed Acute Lymphoblastic Leukemia | Lymphoid Leukemia

United States
National Cancer Institute (NCI)

Completed

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

B-cell Adult Acute Lymphoblastic Leukemia | Acute Undifferentiated Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell... and other conditions

United States
Ehab L Atallah

Terminated

Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

Relapsed or Refractory Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia | Relapsed or Refractory Lymphoblastic Lymphoma

United States
St. Jude Children's Research Hospital

Active, not recruiting

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Refractory

United States
National Cancer Institute (NCI)

Completed

Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Acute Leukemias of Ambiguous Lineage | Untreated Adult Acute Lymphoblastic Leukemia | Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia

United States
St. Jude Children's Research Hospital
AbbVie

Recruiting

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

Refractory Acute Lymphoblastic Leukemia | Relapsed Acute Lymphoblastic Leukemia

United States
Andrew E. Place, MD
University of Colorado, Denver; AbbVie; Boston Children's Hospital; Gateway for... and other collaborators

Recruiting

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Acute Lymphoblastic Leukemia, in Relapse | Therapy-Related Myelodysplastic Syndrome | Acute Leukemia of Ambiguous Lineage | Acute Leukemia of Ambiguous Lineage in Relapse | Myelodysplastic Syndromes, Previously Treated | Acute Lymphoblastic Leukemia With Failed Remission | Myelodysplastic Syndromes... and other conditions

United States
St. Jude Children's Research Hospital
Pfizer

Terminated

Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia With Failed Remission

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

Refractory Acute Lymphoblastic Leukemia | Philadelphia-Negative ALL | Philadelphia-Positive ALL | Refractory Acute Lymphoblastic Leukemia (ALL) | Relapsed ALL, Adult | Refractory Acute Lymphoid Leukemia in Relapse

United States
Syndax Pharmaceuticals

Active, not recruiting

A Study of SNDX-5613 in Combination With Chemotherapy in Participants With R/R Acute Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Undifferentiated Leukemia | Relapsed/Refractory Leukemias | Mixed Phenotype Acute Leukemia

United States, Canada
Mundipharma Research Limited
Innovative Therapies For Children with Cancer Consortium

Terminated

Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma. (BCX1777-108)

Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia | B-cell Precursor Acute Lymphoblastic Leukaemia | T-cell Non-Hodgkin's Lymphoma

Czech Republic, Austria, France, Germany, Italy, United Kingdom
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia

Recurrent Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Non-T, Non-B Childhood Acute Lymphoblastic Leukemia

United States
St. Jude Children's Research Hospital

Recruiting

Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

Pediatric ALL | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Refractory

United States
Children's Mercy Hospital Kansas City

Completed

Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia

Refractory Acute Myeloid Leukemia | Refractory Acute Lymphoblastic Leukemia | Relapsed Pediatric AML | Relapsed Pediatric ALL

United States
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia (PALL)

Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia

United States, France, Spain, United Kingdom
University of Birmingham
AstraZeneca; Cancer Research UK

Terminated

International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia (SeluDex)

Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia Recurrent

United Kingdom, Denmark, Netherlands
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia

Recurrent Childhood Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic Leukemia

United States
Cedars-Sinai Medical Center
Amgen

Active, not recruiting

Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL

B-ALL | B-Cell Acute Lymphoblastic Leukaemia | ALL, Adult

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Studying Biomarkers as a Diagnostic Tool in Samples From Younger Patients With B-Cell Acute Lymphoblastic Leukemia

Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Response or Resistance to Chemotherapy in Young Patients With Acute Lymphoblastic Leukemia Treated With Methotrexate

Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia

United States
Stanford University
Celgene Corporation

Terminated

Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Leukemia | Relapsed Adult Acute Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Acute Bilineal Leukemia | Acute Biphenotypic Leukemia | T Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia

United States
Sanofi

Terminated

SAR3419 in Acute Lymphoblastic Leukemia (MYRALL)

Acute Lymphocytic Leukaemia

United States, France
Children's Hospital Medical Center, Cincinnati

Terminated

Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma (SIR-MO-1101)

Recurrent Adult Lymphoblastic Lymphoma | Refractory Acute Lymphoblastic Leukemia | Refractory Lymphoblastic Lymphoma | Relapsed Lymphoblastic Leukemia

United States
Therapeutic Advances in Childhood Leukemia Consortium

Terminated

Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia

Relapsed Acute Lymphoblastic Leukemia | Relapsed Acute Myelogenous Leukemia

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients (ENSIGN)

B-cell Acute Lymphoblastic Leukemia | Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia

United States
PeproMene Bio, Inc.
City of Hope Medical Center

Recruiting

BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

United States
University of Pennsylvania

Terminated

Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

United States
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute:Dana- Farber/Children's Hospital

Active, not recruiting

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Relapsed B-Cell Acute Lymphoblastic Leukemia

United States
Stanford University
National Cancer Institute (NCI)

Completed

Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

B-cell Adult Acute Lymphoblastic Leukemia (ALL) | Ph-positive Adult Acute Lymphoblastic Leukemia (ALL) | Recurrent Adult Acute Lymphoblastic Leukemia (ALL) | T-cell Adult Acute Lymphoblastic Leukemia (ALL)

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recurrent Adult Lymphoblastic Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia | Refractory Lymphoblastic Lymphoma

United States
Northwestern University
National Cancer Institute (NCI)

Terminated

Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Refractory Adult Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 | Refractory Childhood Acute Lymphoblastic Leukemia

United States
University of Minnesota
Children's Cancer Research Fund United States

Terminated

Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors

Lymphoblastic Lymphoma | Brain Tumors | Lymphoblastic Leukemia, Acute, Childhood | Lymphoblastic Leukemia | Leukemia, Lymphocytic, Acute | Leukemia, Lymphoblastic, Acute | Brain Neoplasms, Malignant | ALL, Childhood | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Lymphoblastic Leukemia, Acute | Leukemia... and other conditions

United States
M.D. Anderson Cancer Center

Withdrawn

STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis

Acute Myeloid Leukemia (AML) | Refractory T Acute Lymphoblastic Leukemia

United States
Fred Hutchinson Cancer Research Center/University...
National Cancer Institute (NCI)

Completed

Reduced Intensity Donor Stem Cell Transplant in Treating Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission

Adult Acute Lymphoblastic Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

T-cell Childhood Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic Leukemia

United States
Massachusetts General Hospital
Millennium Pharmaceuticals, Inc.

Completed

Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | B-cell Adult Acute Lymphoblastic Leukemia | T-cell Adult Acute Lymphoblastic Leukemia

United States
Therapeutic Advances in Childhood Leukemia Consortium
GlaxoSmithKline; Novartis

Terminated

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

Relapsed T-Cell Acute Lymphoblastic Leukemia | Relapsed T-Cell Lymphoblastic Lymphoma

United States, France, Canada, Australia, Austria, Italy, Netherlands
Autolus Limited

Completed

CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (AMELIA)

Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | Refractory Childhood Acute Lymphoblastic Leukemia

United Kingdom
University College, London
Cancer Research UK; Stichting Hemato-Oncologie voor Volwassenen Nederland

Completed

A Study for Older Adults With Acute Lymphoblastic Leukaemia (UKALL60+)

Acute Lymphoblastic Leukaemia

United Kingdom, Netherlands
Therapeutic Advances in Childhood Leukemia Consortium
Enzon Pharmaceuticals, Inc.

Terminated

EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

Lymphoblastic Leukemia, Acute, Childhood | Leukemia, Lymphoblastic, Acute | Lymphoblastic Leukemia, Acute | Leukemia, Lymphoblastic, Acute, T Cell

United States, Australia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States

Clinical Trials on Relapsed Acute Lymphoblastic Leukemia in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations